Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus SERVISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus SERVISONE.
CORTENEMA vs SERVISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
SERVISONE is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors, modulating gene transcription, and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
10-20 mg orally once daily in the morning; higher doses up to 40 mg daily for severe cases.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Terminal elimination half-life is 3-4 hours. Clinically, this supports twice-daily dosing for sustained effect.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal (70-80% as metabolites, 5-10% unchanged); fecal/biliary (15-20%)
Category C
Category C
Corticosteroid
Corticosteroid